{
    "id": 13349,
    "fullName": "DCTN1 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "DCTN1-ALK results from the fusion of DCTN1 and ALK, demonstrating constitutive kinase activity, increased Pi3k and Mapk signaling, and tumor formation in xenograft models (PMID: 24445538). DCTN1-ALK fusions have been identified in uterine inflammatory myofibroblastic tumor and lung cancer (PMID: 26062823, PMID: 28970558).",
            "references": [
                {
                    "id": 11127,
                    "pubMedId": 28970558,
                    "title": "Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28970558"
                },
                {
                    "id": 11042,
                    "pubMedId": 26062823,
                    "title": "STUMP un\"stumped\": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26062823"
                },
                {
                    "id": 3819,
                    "pubMedId": 24445538,
                    "title": "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24445538"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1639,
        "geneSymbol": "DCTN1",
        "terms": [
            "DCTN1",
            "DAP-150",
            "DP-150",
            "P135"
        ]
    },
    "variant": "DCTN1 - ALK",
    "createDate": "10/28/2015",
    "updateDate": "04/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 14203,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in an objective response in a pediatric patient with inflammatory myofibroblastic tumor harboring DCTN1-ALK fusion (J Clin Oncol 36, 2018 (suppl; abstr 10536); NCT02650401).",
            "molecularProfile": {
                "id": 14181,
                "profileName": "DCTN1 - ALK"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11509,
                    "pubMedId": null,
                    "title": "Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.",
                    "url": "https://meetinglibrary.asco.org/record/162773/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13277,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Xalkori (crizotinib) and Votrient (pazopanib) combination treatment resulted in partial response for more than 6 months in a patient with uterine inflammatory myofibroblastic tumor harboring DCTN1-ALK fusion (PMID: 26062823; NCT01548144).",
            "molecularProfile": {
                "id": 14181,
                "profileName": "DCTN1 - ALK"
            },
            "therapy": {
                "id": 1153,
                "therapyName": "Crizotinib + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11042,
                    "pubMedId": 26062823,
                    "title": "STUMP un\"stumped\": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26062823"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14181,
            "profileName": "DCTN1 - ALK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}